Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

84.81USD
23 Aug 2017
Change (% chg)

$-0.99 (-1.15%)
Prev Close
$85.80
Open
$85.21
Day's High
$87.05
Day's Low
$84.75
Volume
161,340
Avg. Vol
373,134
52-wk High
$87.05
52-wk Low
$31.39

Latest Key Developments (Source: Significant Developments)

Alnylam Pharmaceuticals reports Q2 adj loss per share $1.07
Wednesday, 9 Aug 2017 04:00pm EDT 

Aug 10 (Reuters) - Alnylam Pharmaceuticals Inc -:Alnylam Pharmaceuticals reports second quarter 2017 financial results and highlights recent period activity.Q2 non-gaap loss per share $1.07.Q2 revenue $15.9 million versus $8.7 million.Q2 revenue view $22.3 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-1.22 -- Thomson Reuters I/B/E/S.Alnylam Pharmaceuticals Inc - remains on track to end 2017 with greater than $1.0 billion in cash, cash equivalents and fixed marketable securities.Q2 earnings per share view $-1.22, revenue view $22.3 million -- Thomson Reuters I/B/E/S.  Full Article

Alnylam Pharmaceuticals and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study
Monday, 10 Jul 2017 09:30am EDT 

July 10 (Reuters) - Alnylam Pharmaceuticals Inc :Alnylam and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study with investigational RNAI therapeutic Fitusiran in patients with hemophilia A and B with or without inhibitors.Says majority of adverse events were mild/moderate in severity, with most common ae's consisting transient, mild injection site reactions.Says with up to 20 months of dosing, fitusiran safety and tolerability profile remains encouraging in the study.Says there was one discontinuation in study due to AE, an asymptomatic alanine aminotransferase elevation in patient with hcv infection.Says expect initial results of atlas phase 3 program in mid-to-late 2019.  Full Article

Alnylam and Sanofi Genzyme initiate ATLAS Phase 3 program with investigational RNAi therapeutic fitusiran
Friday, 7 Jul 2017 07:30am EDT 

July 7 (Reuters) - Alnylam Pharmaceuticals Inc :Alnylam and Sanofi Genzyme initiate ATLAS phase 3 program with investigational RNAi therapeutic fitusiran.Says expect top-line data from the ATLAS trials in mid-to-late 2019.says ATLAS studies are expected to enroll about 250 patients across 3 separate trials conducted around the world.Says ATLAS to evaluate safety and efficacy of Fitusiran across broad spectrum of patients living with hemophilia.  Full Article

Alnylam and Sanofi Genzyme to present new clinical trial results at the International Society of Thrombosis And Haemostasis Congress
Monday, 26 Jun 2017 04:01pm EDT 

June 26 (Reuters) - Alnylam Pharmaceuticals Inc :Alnylam and Sanofi Genzyme to present new clinical trial results at the International Society Of Thrombosis And Haemostasis (isth) Congress.Alnylam and Sanofi Genzyme to present new clinical trial results at the International Society Of Thrombosis And Haemostasis (isth) Congress.  Full Article

FDA grants Breakthrough Therapy Designation for Alnylam’S Givosiran for prophylaxis of attacks in patients with acute hepatic porphyria
Wednesday, 31 May 2017 07:30am EDT 

May 31 (Reuters) - Alnylam Pharmaceuticals Inc :FDA grants Breakthrough Therapy Designation for Alnylam’S Givosiran for the prophylaxis of attacks in patients with acute hepatic porphyria.Company plans to initiate phase 3 clinical program in late 2017.‍Updated results from trial to be provided in oral presentation on June 26 at International Congress On Porphyrins and Porphyrias​.  Full Article

Alnylam Pharmaceuticals prices public offering of common stock
Wednesday, 24 May 2017 09:00am EDT 

May 24 (Reuters) - Alnylam Pharmaceuticals Inc :Alnylam Pharmaceuticals prices public offering of common stock.Says public offering of 5.00 million common shares priced at $71.87 per share.  Full Article

Alnylam Pharmaceuticals reports proposed public offering of common stock
Tuesday, 23 May 2017 04:04pm EDT 

May 23 (Reuters) - Alnylam Pharmaceuticals Inc ::Alnylam Pharmaceuticals announces proposed public offering of common stock.Says offering 5.00 million common shares.  Full Article

Alnylam Pharmaceuticals appoints Manmeet Soni as chief financial officer
Tuesday, 9 May 2017 08:00am EDT 

May 9 (Reuters) - Alnylam Pharmaceuticals Inc ::Alnylam Pharmaceuticals Inc - appointment of Manmeet S. Soni as chief financial officer.  Full Article

Alnylam Pharmaceuticals files for potential mixed shelf offering
Friday, 5 May 2017 08:49am EDT 

May 5 (Reuters) - Alnylam Pharmaceuticals Inc : :Files for potential mixed shelf offering; size not disclosed .  Full Article

Alnylam Pharmaceuticals reports Q1 loss per share of $1.25 including items
Friday, 5 May 2017 08:00am EDT 

May 5 (Reuters) - Alnylam Pharmaceuticals Inc :Alnylam pharmaceuticals reports first quarter 2017 financial results and highlights recent period activity.Q1 revenue $19 million versus I/B/E/S view $23.6 million.Q1 loss per share $1.25 including items.  Full Article

BRIEF-Alnylam Pharmaceuticals reports Q2 adj loss per share $1.07

* Alnylam Pharmaceuticals reports second quarter 2017 financial results and highlights recent period activity